Articles related to Obstetrics & Gynecology

In this Q&A, Dr. Gautam Borthakur from the University of Texas MD Anderson Cancer Center talks with Clinical Advances in Hematology & Oncology about the goals, treatment options (including tailored treatment), differences in de novo vs. therapy-related, and other suggestions in patients with core-binding factor acute myeloid leukemia (AML).

The CDC’s Advisory Committee on Immunization Practices (ACIP) stated goal for deploying a COVID-19 vaccine is “to decrease death and serious disease as much as possible.” According to José Romero, MD, Chair of the ACIP, the decision to vaccinate health care workers first is based on the actions that will help control the pandemic fastest.

According to a new study in the American Journal of Emergency Medicine, weakness, poor blood sugar control, and gastrointestinal complaints can now be added to the known symptoms of COVID-19, which included fever, coughing, and shortness of breath. Researchers analyzed 12,000 adult patients in New York City emergency departments to compile the data.

We’ve been hearing about hydroxychloroquine seemingly since the pandemic started, and there is no question that doctors need to determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with COVID-19. Does this Original Investigation from JAMA finally provide some clarity to the drug’s use among patients hospitalized with the virus?

For a busy physician, exercise often happens whenever there is time. In a review published in Integrative Medicine Research, the authors looked at the relationship between exercise type and time of day to enhance aerobic capacity, muscle power, and well-being. Read on to find out if the authors used the complex science to truly discover whether there is a “best time.”

Another win for Merck and Keytruda, as the FDA granted accelerated approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 based on PFS. The FDA also approved a companion diagnostic, PD-L1 IHC 22C3 pharmDx.